Lourd Capital LLC Buys Shares of 1,571 Allergan plc (AGN)

Share on StockTwits

Lourd Capital LLC bought a new position in shares of Allergan plc (NYSE:AGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,571 shares of the company’s stock, valued at approximately $299,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Summit Trail Advisors LLC boosted its position in Allergan by 13,646.4% during the 1st quarter. Summit Trail Advisors LLC now owns 1,199,371 shares of the company’s stock worth $1,199,000 after acquiring an additional 1,190,646 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its position in Allergan by 3,032.4% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock worth $146,337,000 after acquiring an additional 849,719 shares during the last quarter. Renaissance Technologies LLC boosted its position in Allergan by 27,066.5% during the 2nd quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock worth $131,347,000 after acquiring an additional 784,928 shares during the last quarter. Mainstay Capital Management LLC ADV boosted its position in Allergan by 13,097.2% during the 2nd quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock worth $4,288,000 after acquiring an additional 669,924 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in Allergan by 16.3% during the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after acquiring an additional 668,343 shares during the last quarter. 77.38% of the stock is owned by institutional investors and hedge funds.

In other Allergan news, Director Joseph H. Boccuzi purchased 900 shares of the business’s stock in a transaction on Thursday, August 30th. The stock was acquired at an average price of $190.59 per share, with a total value of $171,531.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were acquired at an average cost of $190.64 per share, with a total value of $1,906,400.00. The disclosure for this purchase can be found here. Corporate insiders own 0.37% of the company’s stock.

A number of research firms have weighed in on AGN. Mizuho reaffirmed a “hold” rating and set a $194.00 price target on shares of Allergan in a research report on Monday, July 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $180.00 price target on shares of Allergan in a research report on Friday, September 14th. Zacks Investment Research raised Allergan from a “hold” rating to a “buy” rating and set a $197.00 price target for the company in a research report on Wednesday, July 11th. Piper Jaffray Companies set a $164.00 price target on Allergan and gave the stock a “hold” rating in a research report on Monday, September 17th. Finally, Wells Fargo & Co set a $232.00 price target on Allergan and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $211.91.

NYSE AGN opened at $183.28 on Friday. The company has a market capitalization of $64.66 billion, a PE ratio of 11.21, a P/E/G ratio of 1.47 and a beta of 1.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85. Allergan plc has a 12 month low of $142.81 and a 12 month high of $207.24.

Allergan (NYSE:AGN) last released its quarterly earnings data on Thursday, July 26th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.13 by $0.29. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $3.92 billion. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.02 EPS. On average, sell-side analysts forecast that Allergan plc will post 16.29 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 17th. Stockholders of record on Friday, August 17th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.57%. The ex-dividend date of this dividend was Thursday, August 16th. Allergan’s payout ratio is presently 17.61%.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Read More: What is the Dow Jones Industrial Average (DJIA)?

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply